Heart Failure
Conditions
Brief summary
A comprehensive understanding of the socio-demographic, clinical, and biological characteristics of patients with heart failure is essential to develop novel strategies for improving outcomes. The identification of the barriers to guideline-directed medical therapy implementation in a real-world setting is critical to decreasing the risk of heart failure hospitalization and mortality. A comprehensive and well-designed heart failure registry can determine the clinical characteristics of patients with heart failure, identify patient, physician, and healthcare system-related factors for the non-use of evidence-based therapies, and improve the implementation of guideline-directed medical therapy. It should be noted that the number of heart failure registries that enroll patients with de novo heart failure, chronic heart failure (outpatients), and worsening of heart failure (hospitalized or treated in the emergency department), with all three relevant ejection fraction categories (heart failure with reduced ejection fraction, heart failure with mildly-reduced ejection fraction, and heart failure with preserved ejection fraction), is limited. Furthermore, only a few registries assess detailed aspects of guideline adherence, treatment decisions, and both in-hospital and long-term outcomes. Therefore, the Türkiye Heart Failure (TURK-HF) registry has been designed to address this gap in knowledge about the identification, management, and long-term prognosis of patients with heart failure in a real-world setting.
Interventions
Treated with optimal guideline-directed medical therapy
Sponsors
Baskent University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Presence of heart failure -
Exclusion criteria
Age \<18 years \-
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Heart failure hospitalization | From enrollment to the end of follow-up period at 12 months |
| Cardiovascular mortality | From enrollment to the end of follow-up period at 12 months |
| Composite of heart failure hospitalization and cardiovascular mortality | From enrollment to the end of follow-up period at 12 months |
Secondary
| Measure | Time frame |
|---|---|
| All-cause mortality | From enrollment to the end of follow-up period at 12 months |
Countries
Turkey (Türkiye)
Contacts
Primary ContactUmut Kocabaş
Outcome results
None listed